İBRAHİM AKIN, Ümit KARADEMİR, ALİ BELGE, CANBERK BALIKÇI, Kerem URAL

Marbofloxacin Overdose: the Culprit for Acute Blindness in a Dog

Bu olgu sunumunda yanlışlıkla yüksek doz marbofloksasin uygulaması sonucunda 4 yaşlı, dişi, terrier melezi bir köpekte gelişen akut körlük vakası irdelenmiştir. Olgu kliniğe ilk başvurduğunda antibiyotik sağaltımı gerektiren bir solunum yolu enfeksiyonu olduğu belirlendi ve marbofloksasin (2.5 mg/kg) reçete edildi. Bu süre içerisinde, büyük hayvan hastalıkları konusunda uzmanlaşmış bir veteriner hekime götürülmüş ve marbofloksasin 3 gün boyunca aşırı dozda (1050 mg/3 gün boyunca toplam doz) uygulanmıştır. Köpek, uygulama sonrasında tekrar kliniğimize getirildiğinde akut körlük mevcuttu. Marbofloksasin toksisite tanısı, diğer ilişkili etiyoloji haricinde klinik, labaratuvar bulgular ve ilacın aşırı doz alımı temel alınarak konuldu. İlk sağaltım uygulaması olarak deksametazon uygulandı. Takip eden haftalarda görüş bozukluğunun olduğu, parlak ışığa tepki vermediği ve engellere takılmadan yürüyemediği tespit edildi. Son literatürlere göre köpeklerde marbofloksasinin aşırı doz uygulanması sonucu gelişen akut körlük ilk kez bildirilmiştir.

Aşırı Doz Marbofloksasin: Bir Köpekte Akut Körlük İçin Olağan Şüpheli

In this case report, a 4 year old female terrier crossbred dog was presented with acute blindness following accidental high dose marbofloxacin administration was discussed. On initial referral to the clinic, a respiratory disease was evident, requiring antibiotic therapy and marbofloxacin (2.5 mg/kg) was prescribed. Meanwhile, patient was transferred to another veterinary practitioner specialized in large animal diseases, marbofloxacin had administered at an over dose (1050 mg/total dose through 3 days). The dog was then introduced back to our clinic with acute bilateral blindness. A diagnosis of marbofloxacin toxicity related to an overdose was made based on clinical examination and laboratory findings, excluding other relevant etiology. Dexamethasone was applied as initial treatment. In the following weeks, vision loss was eminent even without responding to bright light and not able to negotiate the obstacle course. According to the current literature, this is the first report on marbofloxacin overdose related acute blindness in dogs.

PDF

___

Gelatt KN, van der Woerdt A, Ketring KL, Andrew SE, Brooks DE, Biros DJ, Denis HM, Cutler tJ: Enrofloxacin-associated retinal degeneration in cats. Vet Ophthalmol, 4, 99-106, 2001. DOI: 10.1046/j.1463- 2001.00182.x
Giuliano EA, van der Woerdt A: Feline retinal degeneration: Clinical experience and new findings (1994-1997). J Am Anim Hosp Assoc, 35, 511- , 1998. DOI: 10.5326/15473317-35-6-511
Karademir U, Boyacıoğlu M, Kum C, Sekkin S: Comparative pharmacokinetics of enrofloxacin, danofloxacin and marbofloxacin following intramuscular administration in sheep. Small Rumin Res, 133, 111, 2015. DOI: 10.1016/j.smallrumres.2015.09.007
Wilton LV, Pearce GL, Mann RD: A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin, and cefixime examined by observational cohort studies. Br J Clin Pharmacol, 41, 277-284, 1996. DOI: 10.1046/j.1365- 1996.03013.x
Budinger JM: Diphentylthiocarbazone blindness in dogs. Arch Pathol, , 304-310, 1961.
Andersson MI, MacGowan AP: Development of the quinolones. J Antimicrob Chemother, 51, 1-11, 2003. DOI: 10.1093/jac/dkg212
Blum MD, Graham DJ, McCloskey CA: Temafloxacin syndrome: Review of 95 cases. Clin Infect Dis, 18, 946-950, 1994. DOI: 10.1093/clinids/18.6.946
Allan DS, thompson CM, Barr RM, Clark WF, Chin-Yee IH: Ciprofloxacin- associated hemolytic-uremic syndrome. Ann Pharmacother, 36, 1000- , 2002. DOI: 10.1345/aph.1A350
Campi P, Pichler, WJ: Quinolone hypersensitivity. Curr Opin Allergy Clin Immunol, 3 (4): 275-281, 2003.
Abrams-Ogg A, Holmberg DL, Quinn RF, Keller C, Wilcock BP, Claffey FP: Blindness now attributed to enrofloxacin therapy in a previously reported case of a cat with acromegaly treated by cryohypo- physectomy. Can Vet J, 43 (1): 53-54, 2002.
Takayama S, Hirohashi M, Kato M, Shimada H: Toxicity of quinolone antimicrobial agents. J Toxicol Environ Health, 45, 1-45, 1995. DOI: 10.1080/15287399509531978
Glaze MB, Gelatt KN: Feline ophtalmology. In, Gelatt KN (Ed): Veterinary Opthalmology. 3rd ed., 997-1052, Lippincott/Williams &Wilkins, Philadelphia, 1999.
Pallo-Zimmerman LM, Byron JK, Graves tK: Fluoroquinolones: Then and now. Compend Contin Educ Vet, 32 (7): E1-E9, 2010.
Ford MM, Dubielzig RR, Giuliano EA, Moore CP, Narfström KL: Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats. Am J Vet Res, 68, 190-202, 2007. DOI: 10.2460/ ajvr.68.2.190
Wiebe V, Hamilton P: Fluoroquinolone-induced retinal degeneration in cats. J Am Vet Med Assoc, 221, 1568-1571, 2002. DOI: 10.2460/javma. 221.1568
Ramirez CJ, Minch JD, Gay JM, Lahmers SM, Guerra DJ, Haldorson GJ, Schneider t, Mealey KL: Molecular genetic basis for fluoroquinolone- induced retinal degeneration in cats. Pharmacogenet Genomics, 21, 66-75, DOI: 10.1097/FPC.0b013e3283425f44
Haritova AM, Krastev SZ, Santos RR, Schrickx JA, Fink-Gremmels J: ABC transporters in the eyes of dogs and implications in drug therapy. Curr Eye Res, 38, 271-277, 2013. DOI: 10.3109/02713683.2012.754903